Matthew R Avenarius, PhD, BS
Academic Title: Assistant Professor in the College of Medicine
Research Program: Molecular Carcinogenesis and Chemoprevention
As a member of the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC – James, I focus my research on how cells mutate and transform into cancer cells, as well as the role of genetics in the oncogenic process. I’m an assistant professor in the Division of Molecular Pathology at The Ohio State University.
I also serve as the associate director of The James Molecular Pathology Laboratory. In that role, I am deeply involved in the development, validation, and implementation of innovative oncology-based clinical assays, with the goal of improving cancer diagnostic methods. I am also active in clinical case sign out.
My research interests include hereditary predisposition to cancer, genomic approaches to understanding the molecular basis of oncogenesis, and developing molecular strategies to improve cancer diagnostic methods. My current research centers heavily on the genomics of melanoma and smoking-related lung cancer. I am working to better understand the common environmentally induced patterns of mutations and learn more about the genes involved.
I am also working on a project to assess the genetic and prognostic significance of tetraploidy in patients diagnosed with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
I have co-authored many articles in respected peer-reviewed publications, including Genetics in Medicine, Frontiers in Cellular Neuroscience, and Journal of Cell Biology. I review other research work for the journals Molecular Case Studies and Human Pathology. In 2020, I was involved in developing a rapid sequence-based molecular diagnostic assay to detect COVID-19; a patent is pending.
Graduate Program - PhD
- University of Michigan - Rackham Graduate School
Ann Arbor, MI
USA
Undergraduate Degree - BS - Microbiology
- University of Iowa
Iowa City, IA
USA
- University of Michigan - Rackham Graduate School
Email:
matthew.avenarius@osumc.edu- October 7, 2024
Intra-oral extralingual ectomesenchymal chondromyxoid tumour involving the hard palate with molecular confirmation.
Gokozan HN, Avenarius MR, Iwenofu OH
Histopathology
February 19, 2024Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia.
Avenarius MR, Huang Y, Kittai AS, Bhat SA, Rogers KA, Grever MR, Woyach JA, Miller CR
Leukemia
November 24, 2023FindDNAFusion: An Analytical Pipeline with Multiple Software Tools Improves Detection of Cancer-Associated Gene Fusions from Genomic DNA.
Pan X, Tu H, Mohamed N, Avenarius M, Caruthers S, Zhao W, Jones D
J Mol Diagn
October 18, 2023Characteristics and Outcomes of Patients with CLL and CDKN2A/B Deletion by Fluorescence in situ Hybridization.
Teierle SM, Huang Y, Kittai AS, Bhat SA, Grever MR, Rogers KA, Zhao W, Jones D, Byrd JC, Avenarius MR, Heerema NA, Woyach JA, Miller CR
Blood Adv
April 3, 2023Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization results.
Avenarius MR, Huang Y, Hyak J, Byrd JC, Bhat SA, Grever M, Kittai AS, Rogers KA, Jones D, Zhao W, Heerema NA, Abruzzo LV, Woyach J, Miller CR
Hematol Oncol
July 7, 2022EGFR internal tandem duplications in fusion-negative congenital and neonatal spindle cell tumors.
Koo SC, Schieffer KM, Lee K, Gupta A, Pfau RB, Avenarius MR, Stonerock E, LaHaye S, Fitch J, Setty BA, Roberts R, Ranalli M, Conces MR, Bu F, Mardis ER, Cottrell CE
Genes Chromosomes Cancer
March 15, 2022The clinical utility of a risk-modifying SNP to detect carriers for spinal muscular atrophy with increased sensitivity.
Ware G, Miller C, Jones D, Avenarius M
Mol Genet Genomic Med